Page 80 - MEMORIA ANUAL 2018 SEHH-FEHH

GRUPO ESPAÑOL DE SÍNDROMES MIELODISPLÁSICOS (GESMD)
MEMORIA ANUAL 2018
SOCIEDAD ESPAÑOLA FUNDACIÓN ESPAÑOLA
DE HEMATOLOGÍA Y HEMOTERAPIA DE HEMATOLOGÍA Y HEMOTERAPIA
Publicaciones en revistas científicas
• Montes P, Kerick M, Bernal M, Hernández Mohedo F, Jiménez P, Garrido P, Márquez A, Jurado, Martín J, Ruiz-Cabello F. Genomic loss of HLA alleles changes the clinical outcome in low-risk myelodysplastic syndrome patients. Submitted to Oncotarget 2018.
• Montoro J, Gallur L, Merchán B, Molero A, Roldán E, Martínez-Valle F, Villacampa G, Navarrete M, Ortega M, Castellví J, Saumell S, Bobillo S, Bosch F, Valcárcel D. Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes. Ann Hematol. 2018 Aug;97(8):1349-56. doi: 10.1007/s00277- 018-3302-0.
• Palomo L, Malinverni R, Cabezón M, Xicoy B, Arnan M, Coll R, Pomares H, García O, Fuster-Tormo F, Grau J, Feliu E, Solé F, Buschbeck M, Zamora L. DNA methylation profile in chronic myelomonocytic leukemia associates with dis- tinct clinical, biological and genetic features. Epigenetics. 2018;13(1):8-18. doi: 10.1080/15592294.2017.1405199.
• Martín R, Acha P, Ganster C, Palomo L, Dierks S, Fuster-Tormo F, Mallo M, Ademà V, Gómez-Marzo P, De Haro N, Solanes N, Zamora L, Xicoy B, Shirneshan K, Flach J, Braulke F, Schanz J, Kominowski A, Stromburg M, Brockmann A, Trümper L, Solé F, Haase D. Targeted deep sequencing of CD34+ cells from peripheral blood can reproduce bone marrow molecular profile in myelodysplastic syndromes. Am J Hematol. 2018 Jun;93(6):E152-E154. doi: 10.1002/ ajh.25089.
• Barba P, Martino R, Zhou Q, Cho C, Castro-Malaspina H, Devlin S, Esquirol A, Giralt S, Jakubowski AA, Caballero D, Maloy M, Papadopoulos EB, Piñana JL, Fox ML, Márquez-Malaver FJ, Valcárcel D, Solano C, López-Corral L, Sierra J, Perales MA. CD34(+) Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelo- dysplastic Syndrome. Biol Blood Marrow Transplant. 2018 May;24(5):964-972. doi: 10.1016/j.bbmt.2017.12.804.
• Díez-Campelo M, Lorenzo JI, Itzykson R, Rojas SM, Berthon C, Luño E, Beyne-Rauzy O, Pérez-Oteyza J, Vey N, Bargay J, Park S, Cedena T, Bordessoule D, Muñoz JA, Gyan E, Such E, Visanica S, López-Cadenas F, de Botton S, Hernández-Rivas JM, Ame S, Stamatoullas A, Delaunay J, Salanoubat C, Isnard F, Guieze R, Pérez Guallar J, Badiella L, Sanz G, Cañizo C, Fenaux P. Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries. Br J Haematol. 2018 May;181(3):350- 359. doi: 10.1111/bjh.15190.
• Hurtado AM, Luengo-Gil G, Chen-Liang TH, Amaral F, Batta K, Palomo L, Lumbreras E, Przychodzen B, Caparros E, Amigo ML, Dıez-Campelo M, Zamora L, Salido Fiérrez EJ, Maciejewski JP, Ortuño FJ, Vicente V, Del Canizo M, Sole F, Ferrer-Marín F, Wiseman DH, Jerez A. Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDK- N1A in chronic myelomonocytic leukaemia. Br J Haematol. 2018 Aug;182(3):373-383. doi: 10.1111/bjh.15408.
Presentaciones orales en congresos internacionales
• López Cadenas F, Lumbreras E, Xicoy B, Sánchez-García J, Fenaux P, Coll R, Slama B, Hernández-Rivas JA, Thepot S, Bernal T, Arrizabalaga B, Guerci A, Sanz G, Bargay J, Amigo ML, de Paz R, Giagounidis A, Platzbecker U, Nomdedeu B, Jourdan E, Götze KS, Arar A, Hernández-Rivas JM, Del Cañizo C, Díez-Campelo M. Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients with Del(5q) - Preliminary Blinded Analysis of the European Sintra-REV Trial. Blood. 2018;132:468. 60th American Society of Hematology (ASH) Annual Meeting. San Diego, 1-4 de diciembre de 2018.
80